Jobs
-
The US FDA has accepted the filing of the new drug application for its ciclesonide nasal aerosol, according to Nycomed and Sunovion. The product is an HFA formulation of ciclesonide delivered by a metered dose… Read more . . .
-
Canadian biotech company Asmacure has announced that Martin Driscoll will replace Luc Vachon as Chief Executive Officer. Vachon is leaving the company “to pursue other business ventures.” Asmacure is developing an inhaled nictonic receptor agonist,… Read more . . .
-
GSK and Theravance have announced results for two Phase 3 studies of its ICS/LABA combo DPI Relovair for the treatment of COPD. The product combines fluticasone furoate and vilanterol. The companies said that the studies… Read more . . .
-
Jan De Backer, CEO of Antwerp-based FluidDA, calculates that the combination of biomedical imaging and computational fluid dynamics offered by his company has the potential to reduce development costs for OINDPs by hundreds of millions… Read more . . .
-
Aptar Pharma is touting the use of its “Classic” modular spray pump in the recently launched Sprix ketorolac tromethamine nasal spray from Regency Therapeutics. Regency is a new division of Luitpold Pharmaceuticals, which acquired Sprix… Read more . . .
-
Generex Biotechnology has reached an agreement with Amarantus BioSciences regarding Generex’s RapidMist buccal aerosol delivery system. The RapidMist device is a modified metered dose inhaler that delivers the aerosol to the lining of the mouth… Read more . . .
-
Rigel Pharmaceuticals has said that it is raising approximately $130.4 million as the result of a stock offering involving 16.3 million new shares. The company says that it expects the offer to close on or… Read more . . .
-
MAP Pharmaceuticals has submitted a new drug application (NDA) to the US FDA for its Levadex inhaled dihydroergotamine (DHE) for the treatment of migraines. The delivery device used for the product is the company’s proprietary… Read more . . .
-
Cirrus Pharmaceuticals, Inc. is seeking a B.S./M.S. level scientist with dry powder inhaler (DPI) expertise. The candidate should have several years of pharma experience performing DPI pre-formulation, formulation development, and aerosol characterization work. Experience in… Read more . . .
-
Members of the Committee for Medicinal Products for Human Use (CHMP) have indicated that they would vote against approval of Pharmaxis’s marketing application for Bronchitol as a treatment for cystic fibrosis (CF). The CHMP took… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden